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Abstract
Background: Since the beginning of the COVID-19 pandemic, the world’s attention has been focused on better understanding
the relation between the human host and the SARS-CoV-2 virus, as its action has led to hundreds of thousands of deaths.
Objective: In this context, we decided to study certain consequences of the abundant cytokine release over the innate and
adaptive immune systems, inflammation, and hemostasis, comparing mild and severe forms of COVID-19.
Methods: To accomplish these aims, we will analyze demographic characteristics, biochemical tests, immune biomarkers,
leukocyte phenotyping, immunoglobulin profile, hormonal release (cortisol and prolactin), gene expression, thromboelastometry,
neutralizing antibodies, metabolic profile, and neutrophil function (reactive oxygen species production, neutrophil extracellular
trap production, phagocytosis, migration, gene expression, and proteomics). A total of 200 reverse transcription polymerase chain
reaction–confirmed patients will be enrolled and divided into two groups: mild/moderate or severe/critical forms of COVID-19.
Blood samples will be collected at different times: at inclusion and after 9 and 18 days, with an additional 3-day sample for severe
patients. We believe that this information will provide more knowledge for future studies that will provide more robust and useful
clinical information that may allow for better decisions at the front lines of health care.
Results: The recruitment began in June 2020 and is still in progress. It is expected to continue until February 2021. Data analysis
is scheduled to start after all data have been collected. The coagulation study branch is complete and is already in the analysis
phase.
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Conclusions: This study is original in terms of the different parameters analyzed in the same sample of patients with COVID-19.
The project, which is currently in the data collection phase, was approved by the Brazilian Committee of Ethics in Human Research
(CAAE 30846920.7.0000.0008).
Trial Registration: Brazilian Registry of Clinical Trials RBR-62zdkk; https://ensaiosclinicos.gov.br/rg/RBR-62zdkk
International Registered Report Identifier (IRRID): DERR1-10.2196/24211
(JMIR Res Protoc 2021;10(3):e24211) doi: 10.2196/24211
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Introduction
COVID-19 emerged in the city of Wuhan, Hubei, China and
spread worldwide over the next several months [1]. Originally
reported by the World Health Organization (WHO) as a
pneumonia outbreak of undetermined origin, COVID-19 had
its epidemiological status revised by the WHO as a Public
Health Emergency of International Concern by the end of
January 2020 and as a pandemic at the beginning of March 2020
[2]. The etiologic agent was identified as a new coronavirus of
the Betacoronavirus genus, named SARS-CoV-2, due to its
structural similarity to severe acute respiratory syndrome–related
coronavirus (SARS-CoV), which also accounted for an outbreak
in China in 2002-2003 [3]. The disease is characterized by fever,
cough, and dyspnea, and can progress to pulmonary failure and
lead to liver, heart, and kidney damage. Clinical management
of severe cases requires respiratory assistance [4].
Angiotensin converting enzyme-2 (ACE2) mediates
SARS-CoV-2 (and other coronaviruses) entry via
clathrin-mediated endocytosis into type-2 pneumocytes and
macrophages of the lung milieu [5,6]. ACE2 is a
membrane-bound enzyme that converts active angiotensin II to
inactive angiotensin (1-7). Thus, ACE2 blocks the unfavorable
effects of angiotensin II action, including classic
vasoconstriction in addition to inflammation and thrombosis.
SARS-CoV-2 binding markedly impairs ACE2 catalytic activity
by competitive inhibition, with increased in situ pulmonary
inflammation and coagulation as detrimental outcomes of
weakened counter regulation of the angiotensin II/AT1 receptor
axis [7].
Hence, COVID-19 resembles a hyperimmune syndrome defined
by potentially lethal hypercytokinemia due to overproduction
of a set of proinflammatory mediators, including interleukins
(IL-1β, IL-2, IL7), granulocyte colony stimulating factor,
interferon-gamma (IFN-γ), monocyte chemoattractant protein-1
(MCP-1), and tumor necrosis factor-alpha (TNF-α), which
culminates in multi-organ failure [8,9]. In addition, the
Th17-type response plays an important role in severe cases due
to an additional proinflammatory overflow resulting from
supraphysiological IL-1β, IL-6, and TNF-α levels that contribute
to edema formation [10]. The role of cortisol and prolactin in
the modulation of the immune system has long been described
[11,12], but their participation (if any) in the COVID-19–related
“cytokine storm” remains unknown. Moreover, given the
intimate interplay of inflammation with blood clotting, severe
patients usually show a hypercoagulable profile that leads to an
increased frequency of pulmonary thromboembolism, deep vein
thrombosis, and even heart and brain ischemia events [13,14].
In this context, it is also no surprise that the first treatment that
reduced COVID-19 mortality, in a large randomized controlled
trial (RECOVERY [Randomised Evaluation of COVID-19
Therapy]) [12,15], was dexamethasone, a corticosteroid [12].
However, it also showed that the effect seems to depend on the
clinical stage of the disease, highlighting the need for further
investigations into the course of the inflammatory response.
Other anti-inflammatory treatments such as tocilizumab, an
IL-6 receptor-blocking humanized antibody used to treat
rheumatoid arthritis, were used (out of compassion) in patients
with severe COVID-19 in China and Italy [16-18], with some
clinical improvement. Similarly, another drug under evaluation
is baricitinib, a JAK2 inhibitor approved for myeloproliferative
neoplasms and rheumatoid arthritis that reduces Th17-type
cytokine secretion by blocking AP2-associated protein kinase
1 [19]. However, the clinical efficacy of baricitinib against
COVID-19 has yet to be proven. These studies support the
assumption that a cytokine “storm” not only plays a role in
COVID-19 pathophysiology but also has predictive prognostic
value to monitor the evolution of mild and severe cases.
New metabolomics protocols can characterize metabolic
pathways and provide a broad view of the impact of
SARS-CoV-2 on the body. Both metabolome and proteome
composition are dynamic and reflect genome expression under
specific conditions [20-22]. Furthermore, these innovative
combination protocols can help in understanding the metabolic
profile of a given patient or group of patients [23] from urine,
saliva, and blood samples [24]. The chemical profile
substantially contributed to biological and medical research,
leading to advancements in clinical medical practice [23].
This paper describes the design and rationale of a multicenter
prospective cohort study aimed at evaluating the molecular and
cellular immune signature of COVID-19 by assessing serum
inflammatory mediators and regulatory chemokines of Brazilian
patients with different clinical forms of the disease.
Methods
Study Design and Population
TARGET is registered in the Brazilian Clinical Trials database
with registry code RBR-62zdkk and constitutes a multicenter,
prospective cohort study of consecutive COVID-19 cases,
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consisting of participants recruited from secondary and tertiary
health care facilities in Brazil, namely, the University Hospital
of Brasília (University of Brasília [UnB]) and the public regional
hospitals of Asa Norte, Gama, Santa Maria, and Taguatinga
(Brasília, Distrito Federal). Clinical procedures will be
conducted according to a standard protocol approved by local
institutional review boards under accession number CAAE
30846920.7.0000.0008, with participants included after
voluntary signing of an informed consent form. The study
protocol follows the recommendations of the STROBE
(Strengthening the Reporting of Observational Studies in
Epidemiology) statement for observational studies [16].
Recruitment
Inclusion criteria will include the following: laboratory
confirmation of COVID-19 by reverse transcription polymerase
chain reaction (RT-PCR; KIT Molecular SARS-CoV2 [E/RP];
Bio-Manguinhos), a signed informed consent form, and older
than 18 years. The exclusion criteria are as follows: patients
with inconclusive, unavailable, or solely serological laboratory
diagnosis of COVID-19; a dementia condition (Alzheimer,
Parkinson, vascular frontotemporal, Lewy body, or others);
schizophrenia or schizoaffective disorders with psychotic
characteristics; and patients with previously known congenital
hemorrhagic diseases or thrombophilia or use of anticoagulants
(for coagulation tests; Figure 1).
Figure 1. Inclusion and exclusion criteria flowchart. The T-branch group is patients referred to the emergency room with mild or moderate forms of
COVID-19 not requiring hospitalization. The D-branch group is patients referred to the emergency room with severe or critical forms of COVID-19
requiring hospitalization.
Clinical Assessment Protocol
The clinical evaluation aims to identify the signs and symptoms
associated with COVID-19 and monitor the status
(mild/moderate or severe/critical) of the disease. Clinical
assessments include identification of comorbidities,
COVID-19–associated symptoms and treatment, use of
medications in general, clinical chemistry findings, and life
support regimen care. Severe cases are defined for the purposes
of the study by dyspnea (respiratory rate >30 breaths per minute)
coupled with any of the following criteria: pulsed wave oxygen
saturation <93% at rest, PaO2/FiO2 ≤300 mmHg, respiratory
failure requiring mechanical ventilation, multiple organ failure,
shock, or admission to the intensive care unit. Patients who do
not meet the criteria for severe/critical forms will be considered
mild/moderate cases. No asymptomatic patients will be included
(Textbox 1 and Table 1).
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Textbox 1. Components being assessed for characterization of the following domains: symptoms, comorbidities, treatments, biochemical profile,
immune biomarkers, and leukocyte phenotype and functionality in the TARGET protocol.
Symptoms
Fever, chills, sneezing, sore throat, headache, cough, coryza, anosmia, dysgeusia, diarrhea, asthenia, nausea, vomit, dizziness, and others
Comorbidities
Pulmonary chronic disease, chronic cardiopathy, hypertension, diabetes, chronic kidney disease, pregnancy, neoplasms, smoking, alcohol ingestion,
psoriasis, immunodepression, HIV, Dengue, hanseniasis, Zika virus, chikungunya, Chagas disease, yellow fever, leishmaniasis, malaria, H1N1, and
others
Previous medications
Angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs, and others
Treatments aimed at COVID-19
Clinical support, dexamethasone, enoxaparin, chloroquine, antibiotics, ivermectin, nitazoxanide, lopinavir, ritonavir, remdesivir, immunoglobulin,
plasmapheresis, anti-IL6, JAK inhibitor, and others
Biochemical tests





Ground-glass opacity (<25%, 25-50%, >50%)
Consolidation
Serum immune biomarkers
Chemokines: CXCL8, CCL11, CCL3, CCL4, CCL2, CCL5, and CXCL10; inflammatory cytokines: IL-1β, IL-6, TNF-α, IL-12p70, IFN-gamma,
IL-17A, and IL-15; regulatory cytokines: IL-1Ra, IL-4, IL-5, IL-9, IL-10, and IL-13; and cell growth factors: IL-2, IL-7, FGF-basic, PDGF, VEGF,
G-CSF, and GM-CSF
Gene expression assays
IFN-γ, IL-12, IL-17a, TNF-α, IL-6, IL-4, IL-5, IL-10, IL-1b, RANTES, MCP-1, MIP, MIG, IP-10, and IL-8
Leukocyte phenotyping
CD3, CD4, CD8, HLA-DR, CD25, CD19, CD5, CD27, CD38, PD-1, CD28, CD14, CD16, and CD56
Leukocyte functionality




Isolation, reactive oxygen species production, phagocytosis, neuroendocrine tumors production, migration assay, neutrophil proteomics
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Table 1. The TARGET protocol will collect information about a series of characteristics and tests along the clinical evolution of patients with COVID-19.
At each time point, the following data will be assessed.
Day 18Day 9Day 3Day 0Data registered
———b✓aAge, gender, weight, and height
✓✓✓✓Symptoms
———✓Contact with SARS-CoV-2 patient





















aIndicates data was registered at this time point.
bIndicates data was not registered at this time point.
Timeline
The TARGET protocol comprises two arms, referred to as the
timeline (T)-branch and the days of hospitalization (D)-branch.
For the purposes of this study, the T-branch refers to patients
with mild/moderate forms that did not require hospitalization.
The D-branch refers to patients with severe/critical forms who
required hospital admission. Patients on the T-branch will be
analyzed on days 0, 9, and 18 (T0, T9, and T18), while patients
on the D-branch will be analyzed on days 0, 3, 9, and 18 (D0,
D3, D9, and D18; Figure 1).
Biological Samples
The TARGET protocol encompasses the collection of blood
samples in four different types of containers. For these purposes,
whole peripheral blood samples will be collected in vacuum
tubes without an anticoagulant (10 mL) to obtain serum samples
for metabolomic and biochemical analysis, in sodium citrate (5
mL) for coagulation assays, and in heparin (10 mL) to obtain
plasma samples and to isolate polymorphonuclear and peripheral
blood mononuclear cells (PBMC). Samples will be collected at
distinct time points as follows: day 0, at inclusion by
confirmation of COVID-19; day 3, within 2-4 days after
inclusion; day 9, within 7-10 days after inclusion; and day 18,
within 15-20 days after inclusion (Figure 2).
JMIR Res Protoc 2021 | vol. 10 | iss. 3 | e24211 | p. 5https://www.researchprotocols.org/2021/3/e24211
(page number not for citation purposes)
Kurizky et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Figure 2. Timeline showing the times of blood tests and the analysis performed. The upper line represents the duration of symptoms, a parameter used
in the group of patients enrolled for prospective follow-up, composed primarily of patients who will evolve with mild conditions. The lower line
represents the blood test dates in the hospitalized group: patients who have already entered the study with moderate to severe conditions, usually from
the fifth day of symptom onset.
Preanalytical Sample Handling and Preprocessing
The whole blood samples will be processed to obtain serum or
plasma samples and PBMC batches. Tubes will be centrifuged
at 1900 g for 10 minutes at 22 °C to obtain serum or heparinized
plasma and processed immediately within-facility for routine
PBMC isolation and cryopreservation [17].
Clinical Biochemistry and Hematologic Analysis
Plasma samples obtained in ethylenediamine tetraacetic acid
will be immediately analyzed at local clinical laboratory
facilities. Biochemical analysis will be performed with a Rocas
Cobas E411 system using compatible reagents to assess the
levels of ferritin, troponin T, creatine kinase, creatinine,
aspartate aminotransferase, and alanine aminotransferase. All
procedures will be performed according to the manufacturer’s
recommendations. Cortisol and prolactin in serum samples will
be quantified at the Sabin Medicina Diagnóstica (Brasília,
Brazil) using the chemiluminescent method (Siemens, Advia
Centaur). Hematological analyses will be performed using whole
blood obtained in sodium citrate tubes in an ABBOTT Cell Dyn
3700 analyzer or equivalent with samples from days 0, 9, and
18.
The coagulation profile will be assessed at the DASA Laboratory
(Brasília, Brazil) by thromboelastometry tests carried out within
a 3-hour interval after blood collection [13,25] as follows:
extrinsic system assay (EXTEM), intrinsic system assay
(INTEM), fibrinogen assay (FIBTEM), and nonactivated
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coagulation assay (NATEM; ROTEM, Werfen, Barcelona, Spain; Figure 3).
Figure 3. Thromboelastometry method for clot evaluation. A pin that spins around its own axis is put in contact with a citrated blood sample inside a
cuvette. After recalcification and addition of a specific activator (depending upon the test), the clotting starts, and as it gets firmer, the spinning capacity
of the axis is reduced, which is transformed by the system in a graphic representation of the clot, with increasing amplitude. As the fibrinolysis starts,
the clot becomes less firm, which is represented as decreasing amplitude on the monitor. The extrinsic system assay (EXTEM)'s activator is thromboplastin
and evaluates the extrinsic activation of coagulation. The intrinsic system assay's activator is elagic acid and evaluates the intrinsic activation of
coagulation. The fibrinogen assay's activator is the same as EXTEM plus cytochalasin D, which inhibits platelet activity. This depicts only the participation
of fibrinogen in the clot. The nonactivated coagulation assay is recalcified blood and is a nonactivated evaluation of coagulation. Circulating tissue
factors, such as those expressed on monocytes in inflammatory states, will start the coagulation process. CT is the time frame from activation until an
amplitude of 2 mm and represents thrombin formation. CFT represents the dynamic formation of thrombin and is the time frame between 2 mm and 20
mm of clot amplitude. A10 represents the clot amplitude 10 minutes after initiation and is directly related to MCF, enabling the clinic to make important
decisions. MCF is the maximum amplitude of the clot and represents its main constituents, namely, fibrinogen and platelets. ML represents the percentage
of clot reduction after initiation of fibrinolysis. Therefore, 60 minutes after initiation, thromboelastometry depicts important information about every
phase of the coagulation process. A10: amplitude in 10 minutes; CFT: coagulation formation time; CT: coagulation time; MCF: maximum clot firmness;
ML: maximum lysis.
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Assessment of Molecular and Cellular Immunological
Biomarkers
Serum biomarkers will be assessed using the Luminex Bio-Plex
Pro platform set for 27 human immune mediators (Bio-Rad
Laboratories, California) for the simultaneous assessment of
the following analytes: chemokines (CXCL8, CCL11, CCL3,
CCL4, CCL2, CCL5, and CXCL10), proinflammatory cytokines
(IL-1β, IL-6, TNF-α, IL-12p70, IFN-γ, IL-17A, and IL-15) and
regulatory cytokines (IL-1Ra, IL-4, IL- 5, IL-9, IL-10, and
IL-13), and cell growth factors (IL-2, IL-7, FGF-basic, PDGF,
VEG, G-CSF, and GM-CSF). All procedures will follow the
manufacturer’s recommendations, with levels obtained at days
0, 3, and 9.
The expression levels of immune mediators will be assessed by
TaqMan quantitative RT-PCR (qRT-PCR) assays (Applied
Biosystems, Foster City, CA) for each transcript, with
retro-transcription set up with 1 ng/μL of RNA from PBMCs
and from neutrophils. The reactions will be carried out on a
QuantiStudio 3 Thermal Cycler (Applied Biosystems, CA) in
standard mode [26]. Alternatively, qRT-PCR experiments for
selected genes will be based on the SYBR Green (family of
dyes for molecular biology) detection methodology using the
SYBR Green PCR Master Mix and universal cycling conditions
on the ABI Prism 7000 Sequence Detection System. Expression
levels will be assessed on days 3 and 9.
Immunophenotypic/functional profiles of circulating leukocytes
will be assessed upon short-term culture in vitro. The cell
suspension will be stained with distinct panels of monoclonal
antibodies comprising CD3, CD4, CD8, HLA-DR, CD25, CD19,
CD5, CD27, CD38, PD-1, CD28, CD14, CD16, and CD56 for
cell surface analysis, and IL-1β, IL-6, TNF-α, IFN-α, IL-5-PE,
and IL-10 for evaluation of intracytoplasmic functional status.
Cells will be run on a FORTESSA flow cytometer (BD
Bioscience, CA). An average of 100,000 cells will be analyzed
per sample. The phenotypic/functional parameters will be
assessed using FlowJo software (BD, New Jersey). Leukocyte
phenotyping will be obtained at days 0, 3, and 9.
The immunoglobulin profile will be assessed by multiplexed
PCR using cryopreserved PBMCs [19,27]. Sequencing libraries
will be produced and sequenced using the Illumina MiSeq 2x300
bp platform. For each sample, 1 million reads corresponding to
IgG and IgA will be produced. The reads will be processed
using pRESTO [28], Ig heavy chain genes will be annotated
using the MIXCR platform [29], and clonotypes will be
determined as described in [30]. The immunoglobulin profile
will be assessed in samples obtained on day 3.
Neutrophil Evaluation Experimental Design and
Groups
Neutrophils will be obtained from healthy donors and from
patients at two different times, T9/T18 and D9/D18. Neutrophils
isolated from each donor will be divided into two aliquots and
incubated in buffer (control group) or phorbol 12-myristate
13-acetate (PMA; activated group). Cells from each group will
be submitted to the functional and molecular analyses described
in the following sections.
Neutrophil Isolation and In Vitro Activation
Cell isolation will be performed from peripheral venous blood
by centrifugation in Percoll gradients, as previously described
[27]. The remaining erythrocytes will be removed by hypotonic
lysis. Samples containing >95% neutrophils and >98% viable
neutrophils will be prepared in 50% autologous plasma and
divided into aliquots for control or activation in PMA [28].
Evaluation of Reactive Oxygen Species Production and
Phagocytosis
The isolated neutrophils, after incubation in each condition, will
be tested for reactive oxygen species production as described
by Tahir et al [29].
Evaluation of Neutrophil Extracellular Traps
Production
At the final 20 minutes of incubation in each condition, an
aliquot of neutrophils will be removed and incubated with
SYTOX green (high-affinity nucleic acid stain; 10 µmol/L) and
4′,6-diamidino-2-phenylindole (blue-fluorescent DNA stain; 1
µg/mL). Fluorescence readings will be performed both by
fluorescence microscopy and on a spectrophotometer [30].
Real-time Migration Assay
Neutrophils from each condition will be applied to the upper
chamber of a xCELLigence Real-Time Cell Analysis instrument
and dynamically measured regarding the migration toward the
chemoattractant N-Formylmethionyl-leucyl-phenylalanine
(potent polymorphonuclear leukocyte chemotactic factor) [31].
Neutrophil Proteomics
Neutrophils obtained in all experimental conditions will be
subjected to cell lysis by ultrasound cavitation and then trypsin
digested. Eluted peptides will be subjected to capillary
chromatography in a two-column online vented system. The
fractions will be eluted directly into the ionization chamber of
an Orbitrap Elite mass spectrometer to be analyzed in
data-dependent acquisition mode. The 20 most intense ions will
be selected for high-energy collision dissociation fragmentation,
and the fragments will be analyzed in the ion-trap detector. Mass
spectra will be analyzed for protein quantification and
identification using the Progenesis and Peaks software packages,
as well as in-house developed R scripts for statistical analysis
[32].
Metabolomic Profiling
We will aim to analyze each serum sample collected from mild
(T-branch group) and severe (D-branch group) case patients
and healthy volunteers at each time point in the same manner
(Figures 1 and 2). Untargeted metabolomics will be performed
using a Bruker UPLC-PDA-QqTOF (ultra-performance liquid
c h r o m a t o g r a p h y  p h o t o d i o d e  a r r a y
quadrupole-quadrupole-time-of-flight) compact
(UPLC-MS/MS). The obtained data will be used to build
molecular networking using the Global Natural Products Social
Molecular Networking platform, which gives a better overview
of the metabolic profile and group compound classes in clusters.
For statistical validation of the metabolite differences between
the groups, the data will be processed in MZmine and analyzed
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by means of chemometric tools, as provided by the
MetaboAnalyst platform. Based on this broad chemical outline,
specific metabolites will be quantitatively analyzed using
targeted metabolomics using a CLAE Quadrupole/Quadrupole.
This approach will be used to validate and quantify specific
components of interest, such as metabolites involved in the
glycolytic and hexosamine pathways, and tricarboxylic acid
cycle, among other possible biomarkers.
Sample Size Calculation
The sample size calculation was based on the assumption that
20% of patients who are critically ill have elevated TNF-α levels
compared to 5% of patients who are noncritically ill [8]. TNF
levels will be normalized according to the study population.
Based on a bilateral 95% significance level, a power of 80%,
and a case-control ratio of 1, a sample size of 200 patients can
be predicted.
Statistical Analysis
Clinical and demographic data between groups of patients
(severe vs nonsevere) as well as treatment profiles and
differences in successive time points will be compared. To
compare mean values of soluble biomarkers between groups,
the t student test (or analysis of variance with post hoc test for
multiple groups) or the nonparametric Mann-Whitney (or
Kruskal-Wallis for multiple groups) test will be used as
appropriate, according to the observed sample distribution
features. The SAS 9.3 software (SAS Institute Inc) will be used
with a significance level set at .05. The main binary outcomes
will be analyzed by the estimation of relative risks using a
log-binomial generalized model or by the area under the curve
using trapezoidal methods. All personnel conducting laboratory
procedures will be blinded regarding the patient status (severity
of COVID-19). Receiver operating characteristic curves will
determine cutoff points at which individual or combined scores
of the molecular and cellular biomarkers become informative
of the progression of COVID-19 cases, according to optimal
sensitivity and specificity to identify the signature that best
characterize each clinical status.
Results
This protocol is in the data collection phase. Study recruitment
started in June 2020. At the end of July 2020, 30 T-branch and
85 D-branch patients were enrolled.
We expected to complete all patient inclusion by June 2020,
but with the continuous increase in COVID-19 cases in Brazil,
the authors decided to continue including patients until February
2021.
Data analysis is scheduled to start after all inclusion data have
been collected.
The coagulation study branch, with thromboelastometry, has
already been completed. Preliminary results confirm
deregulation in initiation of the hemostasis process. The results
are currently being analyzed and prepared for publication.
Discussion
This TARGET protocol was designed to standardize the
evaluation of cellular and molecular immune biomarkers to
evaluate their potential as prognosis tools during COVID-19
infection at different degrees of clinical severity. As the host
immune response impacts COVID-19 progression,
understanding the behavior of immune biomarkers at the
different phases of the illness constitutes a crucial step in the
identification of patients who will deteriorate and those who
will benefit most from treatment. A simultaneous comprehensive
assessment of the different aspects of the immune response was
the approach adopted for this protocol.
An early study in China showed that the elevation of certain
biomarkers such as D-dimer, together with inflammatory
markers including ferritin, was associated with the worst
outcomes after SARS-CoV-2 infection [33]. These
measurements have been incorporated in some clinical practice
centers, but their course during disease and actual value in
prognosis are not yet fully described. Higher levels of a series
of other interleukins were also described in severe forms of the
disease [34], contributing to the concept of a cytokine storm,
but their exact significance remains unclear. A thorough
evaluation of different immune aspects could help to clarify
their role.
Less information regarding the cellular immune response has
been published, but its role is progressively gaining more
attention from the scientific community, as some evidence notes
that humoral immunity does not appear to be sufficiently
developed after the first SARS-CoV-2 infection [35]. A
simultaneous evaluation of these two kinds of immune responses
in the TARGET study could help to understand this interface.
Thromboembolism is a recurrent finding among patients with
COVID-19, which has made thromboprophylaxis a vital part
of the available supportive treatment options. Unfortunately,
there is considerable uncertainty about the degree of coagulation
derangement, the possible association with the inflammatory
response elicited including neutrophil extracellular traps [36],
and the consequences of these alterations [13]. Further
knowledge is needed to better understand COVID-19–associated
coagulopathy to provide frontline clinicians with better treatment
options to manage the ensuing clinical manifestations.
A metabolomics study of serum from patients with COVID-19
annotated 941 metabolites. The authors identified metabolic
patterns in severe cases that could be used to propose diagnostic
models capable of predicting progression to severe infection
and assist in the treatment strategy [37]. Observed changes in
the lipid profile (>100 lipids) cause liver damage, as reflected
by abnormal serum levels of bilirubin and bile acids [37].
Another study revealed the consequences of treating patients
with SARS-CoV with methylprednisolone. Disturbances in the
serum lipid profile 12 years post infection were associated with
long-term systemic damage caused by high doses of
methylprednisolone [38]. Metabolomics is therefore a powerful
tool for identifying and monitoring the prognosis and markers
at different stages of a disease, particularly for unknown
infections [24].
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Similarly, neutrophil functional and molecular assays have been
performed in patients with COVID-19 [39], clearly indicating
the participation of these cells in the pathogeny, although no
specific molecular model has yet been proposed [40]. Therefore,
the proteomic approach coupled with further analysis at the
transcription and functional level will provide evidence to
correlate neutrophil activity to the disease severity and time
course.
Only two treatments have shown substantial beneficial effects
to date in randomized trials in COVID-19, with both exhibiting
heterogeneity of treatment effect between subgroups. A
preliminary report from Beigel et al [41] showed that remdesivir
shortened the median recovery in a trial from 15 days in the
placebo group to 11 days, but those on mechanical ventilation
were less likely to benefit. On the other hand, dexamethasone
demonstrated a reduction in mortality at 28 days, but mainly in
those on mechanical ventilation [42]. One possible explanation
for these findings is that an adequate immune response to stop
viral replication is needed at the onset of the disease. The excess
of inflammation presenting is detrimental. As the time when
these treatments are initiated could be key, immune biomarkers
that signal phases of disease to guide the timing of treatments
could be extremely useful in clinical practice.
In summary, TARGET is a translational study that aims to verify
the role of cellular and molecular immune biomarkers in the
prognosis of COVID-19, opening up avenues for their use in
clinical practice. The results that will be achieved are not meant
to be restricted to the description of the disease pathophysiology,
but to form a basis for future clinical studies that will ultimately
help the clinicians on the front line.
Acknowledgments
The authors thank the financial support provided by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq),
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), under process no. 88887.506611/2020-00 and
88887.504420/2020-00 and Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG), under process no. REDE-00140-16.
The authors thank the ArboControl Brazil Project funded by the Ministry of Health, under process no. TED 74/2016 and TED
42/2017 for financial support. The study has been supported by Hospital Universitário de Brasília (HuB) from Universidade de
Brasília (UnB), Hospital Regional da Asa Norte (HRAN). LAN, LFF, OTN, WF and OAMF thank the CNPq for PQ-fellowship
Program. The funders had no contribution in the study design, data collection and analysis, decision to publish or manuscript
preparation. We thank the “Nucleus of Support on Research from Institute Sabin – Brasília for performing hormonal tests and
sample pre-analytical handling, the DASA Laboratory for performing the ROTEM analysis and the Werfen Medical for supplying




1. Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H, et al. The origin, transmission and clinical therapies on coronavirus disease
2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020 Mar 13;7(1):11 [FREE Full text] [doi:
10.1186/s40779-020-00240-0] [Medline: 32169119]
2. Wang TT, Moon HS, Le A, Panchal N. Proceedings of the OMS COVID-19 response conference. J Oral Maxillofac Surg
2020 Aug;78(8):1268-1274 [FREE Full text] [doi: 10.1016/j.joms.2020.05.003] [Medline: 32422192]
3. Yang Y, Peng F, Wang R, Yange M, Guan K, Jiang T, et al. The deadly coronaviruses: the 2003 SARS pandemic and the
2020 novel coronavirus epidemic in China. J Autoimmun 2020 May;109:102434 [FREE Full text] [doi:
10.1016/j.jaut.2020.102434] [Medline: 32143990]
4. Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and
outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States. Diagnosis
(Berl) 2020 May 26;7(2):91-96. [doi: 10.1515/dx-2020-0046] [Medline: 32352401]
5. Conner SD, Schmid SL. Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis.
J Cell Biol 2002 Mar 04;156(5):921-929 [FREE Full text] [doi: 10.1083/jcb.200108123] [Medline: 11877461]
6. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
Eur J Intern Med 2020 Jun;76:14-20 [FREE Full text] [doi: 10.1016/j.ejim.2020.04.037] [Medline: 32336612]
7. Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, Prindle T, Fulton WB, Wang S, et al. Attenuation of pulmonary ACE2
activity impairs inactivation of des-Arg bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J
Physiol Lung Cell Mol Physiol 2018 Jan 01;314(1):L17-L31 [FREE Full text] [doi: 10.1152/ajplung.00498.2016] [Medline:
28935640]
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in
Wuhan, China. Lancet 2020 Feb 15;395(10223):497-506 [FREE Full text] [doi: 10.1016/S0140-6736(20)30183-5] [Medline:
31986264]
9. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration‚ UK.
COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020 Mar 28;395(10229):1033-1034
[FREE Full text] [doi: 10.1016/S0140-6736(20)30628-0] [Medline: 32192578]
JMIR Res Protoc 2021 | vol. 10 | iss. 3 | e24211 | p. 10https://www.researchprotocols.org/2021/3/e24211
(page number not for citation purposes)
Kurizky et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
10. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J
Microbiol Immunol Infect 2020 Jun;53(3):368-370 [FREE Full text] [doi: 10.1016/j.jmii.2020.03.005] [Medline: 32205092]
11. Bennardo F, Buffone C, Giudice A. New therapeutic opportunities for COVID-19 patients with Tocilizumab: possible
correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws. Oral Oncol 2020 Jul;106:104659 [FREE Full
text] [doi: 10.1016/j.oraloncology.2020.104659] [Medline: 32209313]
12. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in
hospitalized patients with Covid-19. N Engl J Med 2021 Feb 25;384(8):693-704 [FREE Full text] [doi:
10.1056/NEJMoa2021436] [Medline: 32678530]
13. Mortus JR, Manek SE, Brubaker LS, Loor M, Cruz MA, Trautner BW, et al. Thromboelastographic results and
hypercoagulability syndrome in patients with coronavirus disease 2019 who are critically ill. JAMA Netw Open 2020 Jun
01;3(6):e2011192 [FREE Full text] [doi: 10.1001/jamanetworkopen.2020.11192] [Medline: 32501489]
14. Zhang C, Wu Z, Li J, Zhao H, Wang G. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist
tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020 May;55(5):105954 [FREE Full text] [doi:
10.1016/j.ijantimicag.2020.105954] [Medline: 32234467]
15. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc
Natl Acad Sci U S A 2020 May 19;117(20):10970-10975 [FREE Full text] [doi: 10.1073/pnas.2005615117] [Medline:
32350134]
16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational
studies. Int J Surg 2014 Dec;12(12):1495-1499 [FREE Full text] [doi: 10.1016/j.ijsu.2014.07.013] [Medline: 25046131]
17. Fuss IJ, Kanof ME, Smith PD, Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr
Protoc Immunol 2009 Apr;Chapter 7:Unit7.1. [doi: 10.1002/0471142735.im0701s85] [Medline: 19347849]
18. Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis 2020
Sep;20(9):1012-1013 [FREE Full text] [doi: 10.1016/S1473-3099(20)30262-0] [Medline: 32251638]
19. McDaniel JR, DeKosky BJ, Tanno H, Ellington AD, Georgiou G. Ultra-high-throughput sequencing of the immune receptor
repertoire from millions of lymphocytes. Nat Protoc 2016 Mar;11(3):429-442. [doi: 10.1038/nprot.2016.024] [Medline:
26844430]
20. Yang PL. Chapter 14 - metabolomics and lipidomics: yet more ways your health is influenced by fat. In: Katze MG, Korth
MJ, Law GL, Nathanson N, editors. Viral Pathogenesis: From Basics to Systems Biology. Cambridge, MA: Academic
Press; 2016:181-198.
21. Santos MCD, Morais CLM, Nascimento YM, Araujo JMG, Lima KMG. Spectroscopy with computational analysis in
virological studies: a decade (2006-2016). Trends Analyt Chem 2017 Dec;97:244-256 [FREE Full text] [doi:
10.1016/j.trac.2017.09.015] [Medline: 32287542]
22. Deng W, Rao J, Chen X, Li D, Zhang Z, Liu D, et al. Metabolomics study of serum and urine samples reveals metabolic
pathways and biomarkers associated with pelvic organ prolapse. J Chromatogr B Analyt Technol Biomed Life Sci 2020
Jan 01;1136:121882. [doi: 10.1016/j.jchromb.2019.121882] [Medline: 31809960]
23. Kouskoumvekaki I, Panagiotou G. Navigating the human metabolome for biomarker identification and design of
pharmaceutical molecules. J Biomed Biotechnol 2011;2011. [doi: 10.1155/2011/525497] [Medline: 20936122]
24. Martín-Blázquez A, Díaz C, González-Flores E, Franco-Rivas D, Jiménez-Luna C, Melguizo C, et al. Untargeted
LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer. Sci Rep 2019 Dec 27;9(1):20198.
[doi: 10.1038/s41598-019-55952-8] [Medline: 31882610]
25. Calatzis AGK, Spannagl M, Vorweg M. Targeted treatment of acute haemostatic disorders. ROTEM Analysis. URL: https:/
/www.rotem.de/wp-content/uploads/2016/09/ROTEM_Analysis_delta_platelet_EN_2016-09-website.pdf [accessed
2020-07-20]
26. Zhang T, Li L, Shang Q, Lv C, Wang C, Su B. Circulating miR-126 is a potential biomarker to predict the onset of type 2
diabetes mellitus in susceptible individuals. Biochem Biophys Res Commun 2015;463(1-2):60-63. [doi:
10.1016/j.bbrc.2015.05.017] [Medline: 25986735]
27. Carvalho LO, Aquino EN, Neves ACD, Fontes W. The neutrophil nucleus and its role in neutrophilic function. J Cell
Biochem 2015 Sep;116(9):1831-1836. [doi: 10.1002/jcb.25124] [Medline: 25727365]
28. Aquino EN, Neves ACD, Santos KC, Uribe CE, Souza PEN, Correa JR, et al. Proteomic analysis of neutrophil priming by
PAF. Protein Pept Lett 2016;23(2):142-151. [doi: 10.2174/0929866523666151202210604] [Medline: 26631175]
29. Tahir M, Arshid S, Fontes B, Castro MS, Luz IS, Botelho KLR, et al. Analysis of the effect of intestinal ischemia and
reperfusion on the rat neutrophils proteome. Front Mol Biosci 2018;5:89. [doi: 10.3389/fmolb.2018.00089] [Medline:
30555831]
30. Hule GP, Bargir UA, Kulkarni M, Kambli P, Taur P, Desai M, et al. Does pioglitazone lead to neutrophil extracellular traps
formation in chronic granulomatous disease patients? Front Immunol 2019;10:1739. [doi: 10.3389/fimmu.2019.01739]
[Medline: 31428088]
31. Cano PM, Vargas A, Lavoie J. A real-time assay for neutrophil chemotaxis. Biotechniques 2016;60(5):245-251 [FREE
Full text] [doi: 10.2144/000114416] [Medline: 27177817]
JMIR Res Protoc 2021 | vol. 10 | iss. 3 | e24211 | p. 11https://www.researchprotocols.org/2021/3/e24211
(page number not for citation purposes)
Kurizky et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
32. Cury N, Silva R, Andre M, Fontes W, Ricart C, Castro M, et al. Root proteome and metabolome reveal a high nutritional
dependency of aluminium in Qualea grandiflora Mart. (Vochysiaceae). Plant Soil 2019 Nov 14;446(1-2):125-143. [doi:
10.1007/s11104-019-04323-3]
33. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with
COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 Mar 28;395(10229):1054-1062 [FREE Full text]
[doi: 10.1016/S0140-6736(20)30566-3] [Medline: 32171076]
34. Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis 2020 Jun;95:304-307 [FREE
Full text] [doi: 10.1016/j.ijid.2020.04.061] [Medline: 32344011]
35. Siracusano G, Pastori C, Lopalco L. Humoral immune responses in COVID-19 patients: a window on the state of the art.
Front Immunol 2020;11:1049. [doi: 10.3389/fimmu.2020.01049] [Medline: 32574261]
36. Middleton EA, He X, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil extracellular traps contribute to
immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 2020 Sep 03;136(10):1169-1179 [FREE Full
text] [doi: 10.1182/blood.2020007008] [Medline: 32597954]
37. Song L, Yin Q, Kang M, Ma N, Li X, Yang Z, et al. Untargeted metabolomics reveals novel serum biomarker of renal
damage in rheumatoid arthritis. J Pharm Biomed Anal 2020 Feb 20;180:113068. [doi: 10.1016/j.jpba.2019.113068] [Medline:
31884392]
38. Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered lipid metabolism in recovered SARS patients twelve years after
infection. Sci Rep 2017 Aug 22;7(1):9110. [doi: 10.1038/s41598-017-09536-z] [Medline: 28831119]
39. Didangelos A. COVID-19 hyperinflammation: what about neutrophils? mSphere 2020 Jun 24;5(3). [doi:
10.1128/mSphere.00367-20] [Medline: 32581077]
40. Laforge M, Elbim C, Frère C, Hémadi M, Massaad C, Nuss P, et al. Tissue damage from neutrophil-induced oxidative
stress in COVID-19. Nat Rev Immunol 2020 Sep;20(9):515-516 [FREE Full text] [doi: 10.1038/s41577-020-0407-1]
[Medline: 32728221]
41. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, ACTT-1 Study Group Members. Remdesivir for
the treatment of Covid-19 - final report. N Engl J Med 2020 Nov 05;383(19):1813-1826 [FREE Full text] [doi:
10.1056/NEJMoa2007764] [Medline: 32445440]
42. RECOVERY Collaborative Group. Dexamethasone for COVID-19: preliminary findings. Drug Ther Bull 2020 Sep;58(9):133.
[doi: 10.1136/dtb.2020.000045] [Medline: 32690491]
Abbreviations
ACE2: angiotensin converting enzyme-2
CNPq: Conselho Nacional de Desenvolvimento Científico e Tecnológico
D: days of hospitalization
EXTEM: extrinsic system assay
FIBTEM: fibrinogen assay
IFN-γ: interferon-gamma
INTEM: intrinsic system assay
MCP-1: monocyte chemoattractant protein-1
NATEM: nonactivated coagulation assay
PBMC: peripheral blood mononuclear cells
PMA: phorbol 12-myristate 13-acetate
qRT-PCR: quantitative reverse transcription polymerase chain reaction
RECOVERY: Randomised Evaluation of COVID-19 Therapy
RT-PCR: reverse transcription polymerase chain reaction
SARS-CoV: severe acute respiratory syndrome–related coronavirus
STROBE: Strengthening the Reporting of Observational Studies in Epidemiology
T: timeline
TNF-α: tumor necrosis factor-alpha
UnB: University of Brasília
UPLC-PDA-QqTOF: ultra-performance liquid chromatography photodiode array
quadrupole-quadrupole-time-of-flight
WHO: World Health Organization
JMIR Res Protoc 2021 | vol. 10 | iss. 3 | e24211 | p. 12https://www.researchprotocols.org/2021/3/e24211
(page number not for citation purposes)
Kurizky et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Edited by G Eysenbach; submitted 09.09.20; peer-reviewed by A Allam, E Soto Vega; comments to author 02.12.20; revised version
received 13.12.20; accepted 19.02.21; published 04.03.21
Please cite as:
Kurizky P, Nóbrega OT, Soares AADSM, Aires RB, Albuquerque CPD, Nicola AM, Albuquerque P, Teixeira-Carvalho A, Naves LA,
Fontes W, Luz IS, Felicori L, Gomides APM, Mendonça-Silva DL, Espindola LS, Martins-Filho OA, de Lima SMB, Mota LMH, Gomes
CM
Molecular and Cellular Biomarkers of COVID-19 Prognosis: Protocol for the Prospective Cohort TARGET Study




©Patricia Kurizky, Otávio T Nóbrega, Alexandre Anderson De Sousa Munhoz Soares, Rodrigo Barbosa Aires, Cleandro Pires
De Albuquerque, André Moraes Nicola, Patrícia Albuquerque, Andréa Teixeira-Carvalho, Luciana Ansaneli Naves, Wagner
Fontes, Isabelle Souza Luz, Liza Felicori, Ana Paulo Monteiro Gomides, Dayde Lane Mendonça-Silva, Laila Salmen Espindola,
Olindo Assis Martins-Filho, Sheila Maria Barbosa de Lima, Licia Maria Henrique Mota, Ciro Martins Gomes. Originally published
in JMIR Research Protocols (http://www.researchprotocols.org), 04.03.2021. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is
properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org,
as well as this copyright and license information must be included.
JMIR Res Protoc 2021 | vol. 10 | iss. 3 | e24211 | p. 13https://www.researchprotocols.org/2021/3/e24211
(page number not for citation purposes)
Kurizky et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
